FarmaMondo
FarmaMondo is a Swiss-based pharmaceutical services group, founded 1915, that acts as a one-stop commercialization partner for biotech and pharma innovators distributing innovative and specialty medicines across 40+ emerging markets via 13 wholly-owned subsidiaries and managed access programmes.
- Company typePrivate
- Founded1915
- HeadquartersChiasso, Switzerland
- Headcount101–250
- GTM typeB2B
- OfferingServices
What FarmaMondo does
FarmaMondo is a Swiss-based pharmaceutical services group headquartered in Chiasso, Switzerland, operating since 1915 (originally as Farmacia Centrale) and incorporated as FarmaMondo SA in 1982. The company functions as a one-stop commercialization partner for pharmaceutical and biotech innovators seeking to bring innovative and specialty medicines to patients in 40+ emerging markets across LATAM, APAC, MENA, Russia/CIS, and Europe. Its portfolio spans oncology, haemato-oncology, metabolic orphan, neurology orphan, immunology orphan, dermatology orphan, and ophthalmology orphan therapeutic areas, with 50+ contracted assets and 3000+ registered healthcare provider relationships.
The company operates three core service lines: Commercial Partnerships (end-to-end regulatory, compliance, funding, and logistics support for biotech innovators expanding into emerging markets), Managed Access Name Patient Programmes (paid centralized infrastructure enabling healthcare providers to procure specialty medicines for individual patients prior to local commercial availability), and Medicines Shortages in Hospitals (cross-border sourcing to address essential drug shortages). Underlying capabilities include GDP-compliant facilities validated by SwissMedic and EU GDP guidelines, GDPR-compliant data processes, and temperature-controlled supply chain infrastructure spanning 15-25°C, 2-8°C, and -20°C storage and transport ranges. Distribution is executed through 13 wholly-owned regional subsidiaries in Argentina, Brazil, Uruguay, Hong Kong, Singapore, UAE, Türkiye, Russia, Portugal, Denmark, Lithuania, India, plus the Swiss headquarters and the Farmacia Centrale pharmacy subsidiary.
Revenue is generated through managed services agreements with pharma/biotech partners, transaction fees from named patient programmes, and direct supply contracts with hospitals and healthcare providers. Pricing is bespoke and not publicly disclosed. The company transitioned from family ownership in 2012 to a group of investors and pharma entrepreneurs led by Group CEO Yaron Spigel, and has executed consistent geographic expansion since 2013, with the most recent launches in Uruguay (2023) and India (March 2026). The May 2026 appointment of Natalie Douglas (former IDIS founder) as Independent Board Director explicitly signals upcoming U.S. market entry.
FarmaMondo firmographics
Firmographics- Name
- FarmaMondo
- Legal name
- Farma Mondo SA
- Website
- https://farmamondo.com
- Company type
- Private
- Founded year
- 1915
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- FarmaMondo is a Swiss-based pharmaceutical services group, founded 1915, that acts as a one-stop commercialization partner for biotech and pharma innovators distributing innovative and specialty medicines across 40+ emerging markets via 13 wholly-owned subsidiaries and managed access programmes.
- Ownership category
- akta.pro rank
Where FarmaMondo is headquartered
LocationHeadquarters
- HQ city
- Chiasso
- HQ country
- Switzerland
- HQ region
- Europe
Offices13 records
Markets served
FarmaMondo business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Supply Chain, Operations, Infrastructure, Marketing or Sales, Technology or R&D
Revenue model
- Commercial Partnerships: Revenue generated through partnership agreements with pharmaceutical and biotech companies for commercialization of innovative and specialty medicines in emerging markets. Partners provide products while FarmaMondo handles market access, distribution, and commercialization.
- Managed Access Programmes: Paid Named Patient Programmes (NPPs) providing revenue-based access to innovative specialty medicines for individual patients through healthcare provider requests. Also includes pro-bono compassionate access programmes.
- Hospital Medicines Shortages: Supply of essential medicines to hospitals facing shortages, serving as a trusted business partner for thousands of hospitals, pharmacies, and health agencies to address national supply constraints.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
FarmaMondo product offering
Product offeringCore offering
FarmaMondo is a Swiss-based pharmaceutical group that acts as a B2B commercialization partner for biotech and pharmaceutical innovators seeking to launch innovative and specialty medicines in emerging markets. It offers end-to-end services including commercial partnerships, paid managed access (named patient) programmes, and solutions for hospital drug shortages, supported by 13+ regional subsidiaries, GDP-compliant temperature-controlled logistics, and a 100+ year operating heritage across 40+ countries.
Product overview
FarmaMondo is a Swiss-based pharmaceutical services group offering a one-stop commercialization model for innovative and specialty medicines in emerging markets. The portfolio consists of three core services: Commercial Partnerships (full-service commercialization support for pharma/biotech innovators), Managed Access Name Patient Programmes (paid access programmes for specialty medicines), and Medicines Shortages in Hospitals (addressing essential medicine gaps). The subsidiary Farmacia Centrale handles individual patient prescriptions in Switzerland. FarmaMondo operates across 40+ countries through 13-14 regional affiliates with a portfolio of 50+ contracted assets spanning oncology, haemato-oncology, metabolic orphan, neurology orphan, immunology orphan, dermatology orphan, and ophthalmology orphan therapeutic areas.
Differentiator
Problem solved
Functional benefit
Brands
- Farmacia Centrale: A Swiss pharmacy serving international patients with prescribed medicines, part of the FarmaMondo Group.
Products and services
- Commercial Partnerships End-to-end commercialization partnership for biotech and pharmaceutical firms with innovative products and global expansion goals, covering regulatory, compliance, funding, and global logistics across emerging markets.
- Managed Access Name Patient Programmes Paid managed access programmes for innovative specialty medicines that provide a comprehensive service package for healthcare provider requests for named patient access, with centralized regulatory, compliance, funding, and logistics infrastructure covering multiple non-commercial markets.
- Medicines Shortages in Hospitals Service addressing global hospital drug shortages by partnering with manufacturers and healthcare providers to source and deliver high-quality medicines, managing the entire supply chain, regulatory processes, and financial flows end-to-end.
- Farmacia Centrale Swiss pharmacy with international distribution reach serving individual patients with valid medical prescriptions, operating as a wholly-owned subsidiary of the FarmaMondo Group.
Quantifiable outcome
- Served 40+ emerging markets with 50+ therapies commercialized
- +2 more outcomes
Companies that use FarmaMondo
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
FarmaMondo technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
FarmaMondo partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Kedrion BiopharmacoreFarmaMondo Group and Kedrion Biopharma announced an exclusive partnership agreement for the distribution of Coagadex (human coagulation factor X) across Estonia, Latvia, and Lithuania. FarmaMondo serves as the exclusive distributor for this coagulation factor therapy in the Baltic markets.
Scale indicators7 records
Recent moves20 records
Expansion highlights4 records
FarmaMondo competitors and assessment
Company assessmentDirect peers
- Clinigen Group: UK-listed specialty pharma services group; the market leader in managed access / named-patient programmes and unlicensed medicine supply - directly comparable to FarmaMondo's core managed access and commercialization offering (and previously acquired IDIS, founded by FarmaMondo's new board director Natalie Douglas).
- Bionet: Provider of managed access programmes and unlicensed/specialty medicine distribution across Europe, APAC and LATAM; closely mirrors FarmaMondo's paid NPP and shortage-sourcing services and competes for the same biotech partnership deals.
- World Courier (Cencora): Specialty cold-chain logistics and clinical trial supply business owned by Cencora (formerly AmerisourceBergen); competes with FarmaMondo's GDP-licensed, temperature-controlled transport network (15-25°C / 2-8°C / -20°C) for biopharma distribution contracts.
Emerging players
- IDIS: Founder-led named-patient programme specialist that was acquired by Clinigen Group; its model is the direct antecedent of FarmaMondo's managed access business - Nataline Douglas (now FarmaMondo board director) led IDIS.
- Caligor: U.S.-based specialty distributor and managed access services provider; comparable on the managed access and unlicensed/specialty medicine distribution capability FarmaMondo sells into biotech and healthcare providers.
Broad incumbents
- McKesson: Global pharmaceutical wholesaler and specialty distributor with extensive GDP-licensed infrastructure; competes for the same biopharma commercialization, specialty distribution and access partnerships as FarmaMondo, especially as it expands outside its core U.S./EU footprint.
- Cencora (AmerisourceBergen): One of the two largest U.S. pharmaceutical distributors and owner of World Courier and PharmaLex; overlaps with FarmaMondo on specialty biologics distribution, named-patient programmes and emerging-market commercialization.
- Cardinal Health: Major U.S. pharmaceutical wholesaler expanding into specialty distribution and patient access services; competes with FarmaMondo for biopharma partnerships focused on broadening patient access to specialty and orphan therapies.
- Phoenix Group: Europe's largest pharmaceutical wholesale and distribution group; relevant comparable because it shares FarmaMondo's European footprint (Switzerland, Iberia, Nordics, Baltics) and is increasingly pursuing specialty/biologic distribution across Europe.
- Walgreens Boots Alliance (Pharmacy-led Distribution): Global pharmacy-led health and distribution group including the Alliance Healthcare wholesale network; comparable on pharmaceutical distribution scale and emerging-market presence via pharmaceutical wholesale and specialty medicine distribution.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
FarmaMondo social profiles
Digital presenceFarmaMondo compliance and trust
Trust signalCompliance3 records
FarmaMondo financial estimates
Financial estimateRevenue estimate
Valuation estimate
FarmaMondo leadership team
Management profileNumber of profiles
Profiles20 records
FarmaMondo subsidiaries and ownership
Company hierarchySubsidiaries13 records
FarmaMondo funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
FarmaMondo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about FarmaMondo
What does FarmaMondo do?
FarmaMondo is a Swiss-based pharmaceutical group that acts as a B2B commercialization partner for biotech and pharmaceutical innovators seeking to launch innovative and specialty medicines in emerging markets. It offers end-to-end services including commercial partnerships, paid managed access (named patient) programmes, and solutions for hospital drug shortages, supported by 13+ regional subsidiaries, GDP-compliant temperature-controlled logistics, and a 100+ year operating heritage across 40+ countries.
Is FarmaMondo a public or private company?
FarmaMondo is a private company. It is classified as venture growth investor backed and is currently operating.
When was FarmaMondo founded?
FarmaMondo was founded in 1915. It employs 101 to 250 people.
Where is FarmaMondo based?
FarmaMondo is headquartered in Chiasso, Switzerland, in the Europe region.
How does FarmaMondo make money?
Three revenue lines are on record. Commercial Partnerships are the primary driver. The others are managed Access Programmes and hospital Medicines Shortages.
Who are FarmaMondo's main competitors?
Direct peers on record are Clinigen Group, Bionet and World Courier (Cencora). Emerging players are IDIS and Caligor. Broad incumbents are McKesson, Cencora (AmerisourceBergen), Cardinal Health, Phoenix Group and Walgreens Boots Alliance (Pharmacy-led Distribution).
Does FarmaMondo have an API?
No public API is recorded for FarmaMondo.